Prostate cancer is the third most common cause of cancer-related deaths among men
in the United States. Twenty-five percent to 30% of sporadic castration-resistant
prostate cancers are characterized by defects in DNA repair.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The mutational landscape of lethal castration-resistant prostate cancer.Nature. 2012; 487: 239-243
- PARP inhibitors: a new era of targeted therapy.Maturitas. 2015; 81: 5-9
- The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.Oncogene. 2006; 25: 5864-5874
- Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med. 2009; 361: 123-134
- FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy.Clin Cancer Res. 2015; 21: 4257-4261
- Trapping of PARP1 and PARP2 by clinical PARP inhibitors.Cancer Res. 2012; 72: 5588-5599
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.Br J Cancer. 2016; 114: 723-730
- Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N Engl J Med. 2016; 375: 2154-2164
- DNA-repair defects and olaparib in metastatic prostate cancer.N Engl J Med. 2015; 373: 1697-1708
- PALB2/FANCN: recombining cancer and Fanconi anemia.Cancer Res. 2010; 70: 7353-7359
- PALB2 mutations and breast-cancer risk.N Engl J Med. 2014; 371: 566-568
- Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.Cancer. 2016; 122: 304-311
- Inherited DNA-repair gene mutations in men with metastatic prostate cancer.N Engl J Med. 2016; 375: 443-453
- DNA repair in prostate cancer: biology and clinical implications.Eur Urol. 2017; 71: 417-425
- Successes and challenges of PARP inhibitors in cancer therapy.Front Oncol. 2015; 5: 222
- Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.J Clin Oncol. 2014; 33: 244-250
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Blood. 2013; 121: 2996-3004
- Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.Cancer. 2000; 88: 398-406
- Cancer incidence after localized therapy for prostate cancer.Cancer. 2006; 107: 991-998
- Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study.Prostate. 2017; 77: 437-445
- Acute promyelocytic leukemia after treatment of metastatic castrate-resistant prostate cancer with radium-223.Clin Genitourin Cancer. 2017; 15: e501-e502
- Acute myeloid leukemia after radium-223 therapy: case report.Clin Genitourin Cancer. 2016; ([e-pub ahead of print])https://doi.org/10.1016/j.clgc.2016.11.002
- ClinicalTrials.gov.(Available at:) (Accessed: July 29, 2017)
Article info
Publication history
Published online: July 14, 2017
Accepted:
July 9,
2017
Received:
June 21,
2017
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
